Every 8-K that Bruker Corporation (BRKR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BRKR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRKR filings page.
Bruker Corporation announced that its Board of Directors has declared a quarterly cash dividend on its common stock, $0.01 par value per share, of $0.05 per share. The dividend was declared on August 14, 2026 and is payable on October 7, 2026 to shareholders of record at the close of business on September 21, 2026.
Bruker Corporation reported Q2 2026 revenue of $838.5 million, up 5.2% year over year, with organic growth of 2.8% and double‑digit organic bookings growth in its Scientific Instruments segment. BEST revenue rose 11.9% and BSI revenue increased 4.7%, reflecting strength in semiconductor, energy research, and biopharma markets, while U.S. academic demand remained soft.
GAAP results swung to a loss as a non‑cash goodwill impairment charge of $134.9 million drove a GAAP operating loss of $65.3 million and a GAAP diluted loss per share of $(0.41), versus earnings of $0.05 a year earlier. On a non‑GAAP basis, operating income rose to $118.5 million with margin expanding to 14.1%, and non‑GAAP diluted EPS increased to $0.49 from $0.32. For the first half, revenue grew 3.9% to $1,661.9 million, while free cash flow remained negative.
Bruker updated its 2026 outlook only for currency and tax, now expecting revenue of $3.54 to $3.57 billion, implying 3% to 4% growth, and reaffirming non‑GAAP EPS guidance of $2.10 to $2.15, 15% to 17% above 2025, assuming a 27.5% effective non‑GAAP tax rate.
Bruker Corporation declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend was declared on July 30, 2026 and is payable on September 1, 2026 to shareholders of record at the close of business on August 15, 2026. This action applies specifically to the company’s outstanding Series A preferred shares and reflects the stated 6.375% dividend rate on that class of stock.
Bruker Corporation filed an amended current report to add missing Inline XBRL tags on the cover page for its 6.375% Mandatory Convertible Preferred Stock, Series A. The amendment does not change any prior disclosures.
At the 2026 Annual Meeting held on May 21, 2026, stockholders elected three Class II directors to terms ending at the 2029 Annual Meeting. Laura A. Francis received 136,149,316 votes for and 4,841,094 withheld, John J. Phillips received 139,036,356 for and 1,954,054 withheld, and Hermann F. Requardt received 129,777,851 for and 11,212,559 withheld.
Stockholders approved, on an advisory basis, 2025 compensation for named executive officers with 127,190,553 votes for, 5,748,270 against and 60,390 abstentions. They also ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 by 138,544,738 votes for, 618,216 against and 29,744 abstentions.
Bruker Corporation reported the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Stockholders elected three Class II directors — Laura A. Francis, John J. (Jack) Phillips, and Hermann F. Requardt, Ph.D. — each to serve three-year terms ending at the 2029 annual meeting.
Stockholders approved, on an advisory basis, the 2025 compensation of the company’s named executive officers, with 127,190,553 votes for, 5,748,270 against, and 60,390 abstentions, plus 6,193,485 broker non-votes. They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026, with 138,544,738 votes for, 618,216 against, and 29,744 abstentions.
Bruker Corporation announced that its Board of Directors has declared a quarterly cash dividend on its common stock of $0.05 per share. The dividend was declared on May 14, 2026 and will be paid on July 7, 2026 to shareholders of record at the close of business on June 22, 2026. The dividend applies to Bruker’s common stock with a par value of $0.01 per share.
Bruker Corporation reported mixed first-quarter 2026 results while reaffirming its full-year outlook. Q1 2026 revenue was $823.4 million, up 2.7% year-over-year, but organic revenue declined 4.4% as US academic demand, tariffs, and currency effects weighed on results. GAAP diluted EPS fell to $0.02 from $0.11, and non-GAAP diluted EPS declined to $0.31 from $0.47.
Bruker Scientific Instruments delivered $759.8 million of revenue, up 2.1% with a 5.0% organic decline, while BEST revenue rose 12.8% to $66.9 million with 3.0% organic growth. Management highlighted high single-digit organic bookings growth for the BSI segment and a book-to-bill ratio above 1.0x for the third consecutive quarter.
The company reconfirmed its 2026 guidance for revenue of $3.57 to $3.60 billion, implying 4% to 5% reported growth and 1% to 2% organic growth, and non-GAAP EPS of $2.10 to $2.15, 15% to 17% above 2025 despite an approximately 8% foreign exchange headwind.
Bruker Corporation announced a regular income payment for holders of its 6.375% Mandatory Convertible Preferred Stock, Series A. The Board declared a quarterly cash dividend of $3.9844 per share.
The dividend was declared on April 28, 2026 and will be paid on June 1, 2026 to shareholders of record as of May 15, 2026.
Bruker Corporation announced that Falko Busse, Ph.D., an executive officer and President of the Bruker BioSpin Group, will transition his duties on or around May 1, 2026, with his employment ending on October 31, 2026.
Under a mutual separation agreement with Bruker Switzerland AG, Dr. Busse will receive separation benefits, including severance, a pro-rated bonus, and unused vacation payout totaling an amount in Swiss francs approximately equal to $1,020,351, payable on the separation date. Any unvested equity awards held on that date will be forfeited. The agreement also includes customary restrictive covenants and confidentiality, non-solicitation, and non-disparagement obligations.
Bruker Corporation has expanded its Board of Directors to twelve members and appointed Thierry L. Bernard as a Class III director, effective April 1, 2026. He will serve until the 2027 Annual Meeting of Stockholders.
Bernard is currently CEO and Managing Director of QIAGEN N.V., with a previously announced transition plan under which he will step down once a successor is appointed. His background spans senior roles at bioMérieux and other international life-science companies, as well as board leadership at AdvaMedDx and Neogen Corporation. His compensation as a non-employee director will match Bruker’s existing director compensation program, and the company states there are no related-party transactions requiring disclosure. Bruker will later disclose his Board committee assignments.
Bruker Corporation announced board changes and a new dividend. Director Dr. Cynthia M. Friend will not stand for re-election as a Class II director when her term ends at the 2026 Annual Meeting, and her decision is stated as not due to any disagreement with the company. She will continue to serve until then.
On February 19, 2026, Jack Phillips stepped down as a Class III director and was immediately re-elected as a Class II director, with his board service deemed continuous from January 1, 2026, and his compensation and benefits unchanged. The board also declared a quarterly cash dividend of $0.05 per share on Bruker’s common stock, payable on April 7, 2026 to shareholders of record as of March 23, 2026.
Bruker Corporation reported a challenging 2025, with modest growth but weaker profitability and a GAAP loss. Full-year revenue rose to $3.44 billion, up 2.1% from 2024, yet organic revenue fell 3.7%. Q4-25 revenue was $977.2 million, essentially flat year-over-year.
GAAP operating income dropped to $68.2 million for 2025 from $253.1 million, driven by $127.2 million of goodwill and intangible impairments and $77.4 million of restructuring charges. GAAP diluted loss per share was $(0.15), while non-GAAP diluted EPS was $1.83, down from $2.41.
Management initiated 2026 guidance calling for revenue of $3.57–$3.60 billion, implying 4%–5% growth, with 1%–2% organic growth and non-GAAP EPS of $2.10–$2.15, 15%–17% above 2025 despite an estimated 8% foreign-exchange headwind.
Bruker Corporation released preliminary figures for its fourth quarter ended December 31, 2025 and shared its outlook for 2026 during a presentation at the J.P. Morgan Healthcare Conference. The company currently expects Q4 2025 revenue between $965 million and $970 million, and reported that its Bruker Scientific Instruments segments had a book-to-bill ratio above 1.0, indicating orders exceeded revenue in the period.
For the full year 2026, Bruker is targeting organic revenue growth of flat to up low-single digits, expansion of non-GAAP organic operating margins by 250 to 300 basis points, and non-GAAP earnings per share growth in the double-digits, all compared to 2025. The company emphasized that these figures are preliminary, unaudited and subject to change as year-end closing and audit procedures are completed.
Bruker Corporation furnished an update on its financial performance by announcing a press release with results for the three and nine months ended September 30, 2025. The press release, dated November 3, 2025, is provided as Exhibit 99.1.
The company states this information is being furnished under Item 2.02 and is not deemed “filed” for liability purposes, nor incorporated by reference unless expressly stated. The filing also includes a cautionary note regarding forward‑looking statements tied to the press release.
Bruker Corporation (BRKR) filed a Current Report disclosing arrangements for a new 6.375% Mandatory Convertible Preferred Stock, Series A. The filing lists an Underwriting Agreement dated September 3, 2025 with J.P. Morgan Securities LLC and BofA Securities, Inc. as representatives of the underwriters, a Certificate of Designations and the form of preferred stock certificate, and a legal opinion and consent from Simpson Thacher & Bartlett LLP dated September 8, 2025 regarding the legality of the shares. The exhibit index indicates these documents are attached, but the filing text does not state offering size, pricing, conversion terms, expected use of proceeds, or other economic details.